Darrin Beaupre
IDEAYA Biosciences · Biosplice Therapeutics, Inc. · Pharmacyclics LLC.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Darrin Beaupre as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:27 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05787587 · A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsIDEAYA Biosciences · active not recruiting · Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer · study director
- Ph1NCT05084859 · A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid TumorsBiosplice Therapeutics, Inc. · terminated · Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Colorectal Cancer · study chair
- Ph1NCT03355066 · A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid TumorsBiosplice Therapeutics, Inc. · terminated · Solid Tumor, Adult · study chair
- Ph2NCT01325701 · Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell LymphomaPharmacyclics LLC. · completed · Diffuse Large Cell B-lymphoma · study director
- Ph2NCT01236391 · Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)Pharmacyclics LLC. · completed · Mantle Cell Lymphoma · study director
- Ph1/Ph2NCT00243035 · Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple MyelomaNational Cancer Institute (NCI) · terminated · Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- FARNESYLTRANSFERASE INHIBITORS IN CANCER THERAPYR01CA083978 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI SAID M SEBTI · fiscal years 2000 to 2004Named on NCT00243035
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in multiple myeloma.